Skip to main content
. Author manuscript; available in PMC: 2018 Apr 3.
Published in final edited form as: Phys Med Biol. 2016 Oct 3;61(20):7347–7362. doi: 10.1088/0031-9155/61/20/7347

Figure 6.

Figure 6

2D comparison between gPMC v2.0 and TOPAS for doses in a prostate cancer patient. (a) TOPAS-calculated dose distribution. (b) gPMC v2.0-calculated dose distribution. (c) Relative dose difference of gPMC v1.0 as ((gPMC v1.0 - TOPAS)/prescribed dose). (d) Relative dose difference of gPMC v2.0 as ((gPMC v2.0 - TOPAS)/prescribed dose).